Li Li1, Yanan Wang1, Christine Guo Lian2, Nina Hu2, Hongzhong Jin1, Yuehua Liu1. 1. Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy Medical Sciences, Beijing, China. 2. Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, USA.
Abstract
BACKGROUND: Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia. OBJECTIVE: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis. METHODS: This was a retrospective study of clinical and pathological features of 10 patients with myeloid leukemia cutis. RESULTS: One patient developed skin lesions before the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously. Of these patients, five presented with generalized papules or nodules, and five with localized masses. The biopsy of skin lesions showed a large number of tumor cells within the dermis and subcutaneous fat layer. Immunohistochemical analysis showed strong reactivity to myeloperoxidase (MPO), CD15, CD43 and CD45 (LCA) in most cases. NPM1 (nucleophosmin I) and FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) mutations were identified in one case. Five patients with acute myelogenous leukemia and one patient with chronic myelomonocytic leukemia died within two months to one year after the onset of skin lesions. STUDY LIMITATIONS: This was a retrospective and small sample study. CONCLUSIONS: In patients with myelogenous leukemia, skin infiltration usually occurs after, but occasionally before, the appearance of hemogram and myelogram abnormalities, and the presence of skin infiltration is often associated with a poor prognosis and short survival time. myeloid leukemia cutis often presents as generalized or localized nodules or masses with characteristic pathological and histochemical findings.
BACKGROUND:Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia. OBJECTIVE: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis. METHODS: This was a retrospective study of clinical and pathological features of 10 patients with myeloid leukemia cutis. RESULTS: One patient developed skin lesions before the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously. Of these patients, five presented with generalized papules or nodules, and five with localized masses. The biopsy of skin lesions showed a large number of tumor cells within the dermis and subcutaneous fat layer. Immunohistochemical analysis showed strong reactivity to myeloperoxidase (MPO), CD15, CD43 and CD45 (LCA) in most cases. NPM1 (nucleophosmin I) and FLT3-ITD (Fms-like tyrosine kinase 3-internal tandem duplication) mutations were identified in one case. Five patients with acute myelogenous leukemia and one patient with chronic myelomonocytic leukemia died within two months to one year after the onset of skin lesions. STUDY LIMITATIONS: This was a retrospective and small sample study. CONCLUSIONS: In patients with myelogenous leukemia, skin infiltration usually occurs after, but occasionally before, the appearance of hemogram and myelogram abnormalities, and the presence of skin infiltration is often associated with a poor prognosis and short survival time. myeloid leukemia cutis often presents as generalized or localized nodules or masses with characteristic pathological and histochemical findings.
Authors: J M Klco; J S Welch; T T Nguyen; M Y Hurley; F H Kreisel; A Hassan; A C Lind; J L Frater Journal: Int J Lab Hematol Date: 2011-08-24 Impact factor: 2.877
Authors: Hendrik J M de Jonge; Peter J M Valk; Eveline S J M de Bont; Jan Jacob Schuringa; Gert Ossenkoppele; Edo Vellenga; Gerwin Huls Journal: Haematologica Date: 2011-05-23 Impact factor: 9.941
Authors: Laju M Patel; Amin Maghari; Robert A Schwartz; Rajendra Kapila; Aaron J Morgan; W Clark Lambert Journal: Int J Dermatol Date: 2012-04 Impact factor: 2.736
Authors: Gunnar Wagner; Klaus Fenchel; Walter Back; Alina Schulz; Michael Max Sachse Journal: J Dtsch Dermatol Ges Date: 2011-11-17 Impact factor: 5.584
Authors: Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine Journal: N Engl J Med Date: 2012-03-14 Impact factor: 91.245
Authors: Yeon Soo Kang; Hei Sung Kim; Hyun Jeong Park; Jun Young Lee; Hyung Ok Kim; Baik Kee Cho; Young Min Park Journal: J Korean Med Sci Date: 2013-03-27 Impact factor: 2.153
Authors: Hwa Jung Yook; Joon Ho Son; Yeong Ho Kim; Ju Hee Han; Ji Hyun Lee; Young Min Park; Nack-Gyun Chung; Hee Je Kim; Chul Hwan Bang Journal: Acta Derm Venereol Date: 2022-02-11 Impact factor: 3.875
Authors: Daniel Heudobler; Sebastian Klobuch; Simone Thomas; Joachim Hahn; Wolfgang Herr; Albrecht Reichle Journal: Front Pharmacol Date: 2018-11-13 Impact factor: 5.810